Last reviewed · How we verify
Delayed high-intensity statin
Delayed high-intensity statin is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Beijing Tiantan Hospital. It is currently in Phase 3 development for Hyperlipidemia / dyslipidemia (primary indication inferred from statin class), Cardiovascular disease prevention. Also known as: Delayed Atorvastatin.
A statin formulation designed to achieve high-intensity lipid-lowering effects through delayed or modified release kinetics to reduce LDL cholesterol.
A statin formulation designed to achieve high-intensity lipid-lowering effects through delayed or modified release kinetics to reduce LDL cholesterol. Used for Hyperlipidemia / dyslipidemia (primary indication inferred from statin class), Cardiovascular disease prevention.
At a glance
| Generic name | Delayed high-intensity statin |
|---|---|
| Also known as | Delayed Atorvastatin |
| Sponsor | Beijing Tiantan Hospital |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is a delayed-release statin variant intended to optimize pharmacokinetics and potentially improve tolerability or efficacy compared to standard statin formulations. The delayed-release mechanism may reduce peak plasma concentrations and associated adverse effects while maintaining therapeutic LDL-lowering activity. The specific statin active ingredient and exact release mechanism are not publicly detailed.
Approved indications
- Hyperlipidemia / dyslipidemia (primary indication inferred from statin class)
- Cardiovascular disease prevention
Common side effects
- Myalgia / muscle pain
- Elevated liver enzymes
- Headache
- Gastrointestinal disturbance
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Delayed high-intensity statin CI brief — competitive landscape report
- Delayed high-intensity statin updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI
Frequently asked questions about Delayed high-intensity statin
What is Delayed high-intensity statin?
How does Delayed high-intensity statin work?
What is Delayed high-intensity statin used for?
Who makes Delayed high-intensity statin?
Is Delayed high-intensity statin also known as anything else?
What drug class is Delayed high-intensity statin in?
What development phase is Delayed high-intensity statin in?
What are the side effects of Delayed high-intensity statin?
What does Delayed high-intensity statin target?
Related
- Drug class: All HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting HMG-CoA reductase
- Manufacturer: Beijing Tiantan Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hyperlipidemia / dyslipidemia (primary indication inferred from statin class)
- Indication: Drugs for Cardiovascular disease prevention
- Also known as: Delayed Atorvastatin
- Compare: Delayed high-intensity statin vs similar drugs
- Pricing: Delayed high-intensity statin cost, discount & access